摘要:
Disclosed is a process for producing a crystalline sugar comprising D-psicose and D-allose. Also disclosed is a process for producing the sugar. A complex crystalline sugar comprising D-psicose and D-allose. The compositional ratio between D-psicose and D-allose in the sugar is about 1:1 to 1:4. A process for producing a complex crystalline sugar comprising D-psicose and D-allose, the process comprising producing a complex crystalline sugar comprising D-psicose and D-allose from a sugar solution containing D-psicose and p-allose and collecting the complex crystalline sugar. The solvent of the sugar solution used in the production of the complex crystalline sugar is water or a mixture of water and ethanol. The sugar solution containing D-psicose and D-allose is produced by a process comprising reacting D-psicose with L-rhamnose isomerase to convert D-psicose into D-allose. The L-rhamnose isomerase is derived from a strain (IPOD FERM BP-08593) belonging to Pseudomonas stutzeri.
摘要:
Screening for a glucokinase-activating substance among rare sugars and providing a composition for treating disordered conditions in association with glucokinase activity, the composition containing the glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm, the promoting agent containing D-psicose and/or D-tagatose as the active ingredient, or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and/or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions. The disordered conditions in association with glucokinase activity are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity. The composition is in a pharmaceutical form, and contains D-psicose and/or D-tagatose together with one or more pharmaceutically acceptable carriers.
摘要:
Providing a D-psicose-containing sweetener with the modification of the taste of D-psicose, comprising D-psicose, a sugar alcohol and/or a high intensity sweetener, preferably containing D-psicose as the main component, particularly a low-calorie sweetener and/or a sweetener giving refreshing feel in the oral cavity, as well as foods and drinks obtained by using the D-psicose-containing sweetener with the modification of the taste of D-psicose, and other products given with sweetness. The sugar alcohol is one or more sugar alcohols selected from the group consisting of sorbitol, mannitol, lactitol, maltitol, xylitol and erythritol, while the high intensity sweetener is one or more high intensity sweeteners as selected from aspartame, acesulfame K, sodium cyclamate, sodium saccharin, Sucralose (under trade name), stevia sweetener, dulcin, taumatin, neotame and monellin.
摘要:
A novel use of D-psicose (for suppressing the abnormal intra-day increase of blood glucose level) is provided. A composition containing D-psicose as the active component and for use in suppressing the abnormal intra-day increase of plasma glucose concentration. The composition is a composition in blend with D-psicose and/or a derivative thereof. The composition is in a form selected from sweeteners, seasonings, food additives, food materials, food and drink products, health food and drink products, pharmaceutical products, and feeds and blended with D-psicose, and/or a derivative thereof as the active component, for use in preventing and therapeutically treating diseases requiring the saving of insufficient insulin, the amelioration of insulin sensitivity and the amelioration of hyperglycemia, and/or diseases of which the symptoms can be ameliorated via the suppression of the abnormal intra-day increase of plasma glucose concentration or of which the onset can be prevented via the suppression thereof, such as diabetes mellitus, occult diabetic states, obesity, hyperglycemia, and/or arteriosclerosis. A method for using D-psicose in suppressing the abnormal intra-day increase of plasma glucose concentration, comprising giving D-psicose at given times to suppress the abnormal increase of plasma glucose concentration throughout the day.